Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

 Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

Shots:

  • Amgen entered into an agreement with Abilita Bio for the development of therapies utilizing Abilita’s Enabled Membrane Protein (EMP) technology targeting certain integral membrane proteins
  • The focus of the agreement is to discover and develop candidates targeting complex membrane proteins
  • EMP technology is a drug discovery platform targeting GPCRs, ion channels, and transporters to develop membrane protein target variants in multiple therapy areas

Click here to read full press release/ article | Ref: Abilita Bio | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post